S
3.29
0.02 (0.61%)
| Previous Close | 3.27 |
| Open | 3.26 |
| Volume | 173,350 |
| Avg. Volume (3M) | 448,281 |
| Market Cap | 164,631,920 |
| Price / Sales | 4.48 |
| Price / Book | 5.41 |
| 52 Weeks Range | |
| Earnings Date | 11 Mar 2025 - 17 Mar 2025 |
| Profit Margin | -264.60% |
| Operating Margin (TTM) | -180.99% |
| Diluted EPS (TTM) | -1.95 |
| Quarterly Revenue Growth (YOY) | 164.10% |
| Total Debt/Equity (MRQ) | 447.18% |
| Current Ratio (MRQ) | 4.84 |
| Operating Cash Flow (TTM) | -66.54 M |
| Levered Free Cash Flow (TTM) | -44.98 M |
| Return on Assets (TTM) | -42.02% |
| Return on Equity (TTM) | -166.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | scPharmaceuticals Inc. | Bearish | Bearish |
AIStockmoo Score
1.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.68% |
| % Held by Institutions | 81.64% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (HC Wainwright & Co., 447.11%) | Buy |
| Median | 15.00 (355.93%) | |
| Low | 12.00 (Craig-Hallum, 264.74%) | Buy |
| Average | 15.00 (355.93%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 14 Nov 2024 | 12.00 (264.74%) | Buy | 3.36 |
| HC Wainwright & Co. | 14 Nov 2024 | 18.00 (447.11%) | Buy | 3.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jan 2025 | Announcement | scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results |
| 13 Nov 2024 | Announcement | scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update |
| 06 Nov 2024 | Announcement | scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |